| Trial ID: | L2303 |
| Source ID: | NCT01021865
|
| Associated Drug: |
Glucagon-Like-Peptide-1/Regadenoson/Perflutren Lipid Microsphere
|
| Title: |
Effects of Hyperglycemia on Myocardial Perfusion in Humans With and Without Type 2 Diabetes
|
| Acronym: |
GLP-1
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Coronary Artery Disease|Diabetes Mellitus Type 2
|
| Interventions: |
DRUG: Glucagon-Like-Peptide-1/Regadenoson/Perflutren Lipid Microsphere
|
| Outcome Measures: |
Primary: To determine whether hyperglycemia alters myocardial perfusion in subjects with type 2 diabetes, Nov 2009-2011 | Secondary: To determine whether GLP-1 modulates myocardial perfusion in subjects with type 2 diabetes., Nov 2009-2011
|
| Sponsor/Collaborators: |
Sponsor: Mayo Clinic | Collaborators: University of Nebraska|Astellas Pharma US, Inc.|Lantheus Medical Imaging
|
| Gender: |
ALL
|
| Age: |
ADULT
|
| Phases: |
|
| Enrollment: |
33
|
| Study Type: |
OBSERVATIONAL
|
| Study Designs: |
Observational Model: |Time Perspective: p
|
| Start Date: |
2010-02
|
| Completion Date: |
2014-07
|
| Results First Posted: |
|
| Last Update Posted: |
2015-07-07
|
| Locations: |
Mayo Clinic, Rochester, Minnesota, 55905, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT01021865
|
